SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-16-014349
Filing Date
2016-04-19
Accepted
2016-04-19 16:13:01
Documents
7
Period of Report
2016-05-18
Effectiveness Date
2016-04-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A mirati2016proxy.htm DEF 14A 518437
2 a2016proxyvotingcard1.jpg GRAPHIC 215473
3 g196472a01.jpg GRAPHIC 6478
4 g368600a01.jpg GRAPHIC 3453
5 g641197a03.jpg GRAPHIC 8973
6 g775045a03.jpg GRAPHIC 11606
7 g775045a05.jpg GRAPHIC 11606
  Complete submission text file 0001628280-16-014349.txt   874658
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35921 | Film No.: 161579256
SIC: 2834 Pharmaceutical Preparations